Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Conditions

• Carcinoma
• Intrahepatic Cholangiocarcinoma
• Gallbladder Cancer
• Surufatinib
• Angiogenesis Inhibitors
• Tislelizumab
• Antineoplastic Agents, Immunological
• Immunotherapy

Interventions

• DRUG: HAIC
• DRUG: Surufatinib
• DRUG: Tislelizumab

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology